Molecular cloning of a cDNA for a mouse erythropoietin (Epo) receptor (EpoR) has facilitated the understanding of the structure of this receptor. However, there is, as yet, no explanation for the discrepancy between the protein recognized by specific antibodies against mouse EpoR and the unexpectedly larger species that can be cross-linked t o labeled Epo. It is unclear whether the product of an unidentified gene is included in the EpoR complex. In the present study, we directly compared the cross-linking patterns for human EpoR that were endogenously expressed in three types of Epo-responsive cell, and that was artificially expressed in nonhematopoietic cells after transfection with cDNA for human EpoR. We observed that 85-kD and 105-kD proteins formed ligand-receptor complexes in all the human RYTHROPOIETIN (Epo) is a 34-kD glycoprotein hormone that controls the proliferation and differentiation of erythroid precursor cells both in vitro and in vivo.' The functions of Epo are transmitted through a specific receptor (EpoR) that is expressed on the surface of these cells.' Two major proteins of 85 to 95 kD and 100 to 115 kD have been shown to bind Epo in erythroid progenitor cells and in lines of erythroleukemia cells by cross-linking studie?j since recombinant human Epo first became available. A 63-to 66-kD protein, present at low levels, has also been shown to bind human Epo in mouse erythroleukemia Since D'Andrea et a18 succeeded in molecular cloning of a cDNA for mouse EpoR in 1989, information about this receptor has accumulated. However, a major discrepancy has remained unresolved between results obtained with the mouse EpoR clone and the results of cross-linking studies described by several investigators. Cross-linking studies have shown that human Epo binds proteins of 63 to 66 kD and 105 k D 8 or proteins of 65 kD and 85 k D 9 in COS cells, and proteins of 63 to 66 D, 85 to 95 kD and 100 to 110 kD in mouse myeloidAymphoid cell lines that have been transfected with the mouse EpoR cDNA, re~pectively.~~'~ It appears that the smallest 63-to 66-kD Epo-binding protein shown in cross-linking studies is a product of the cloned mouse EpoR mRNA because the amino acid sequence of E
Epo-responsive cells and, furthermore, that the formation of a complex derived from the 70-kD protein was dependent on the level of expression of the cloned EpoR mRNA in these cells. By contrast, a prominent cross-linked band derived from the 70-kD protein and a weaker band derived from the 80-t o 85-kD protein, but no band derived from the 105-kD protein, could be shown in the case of nonhematopoietic cells transfected with the human EpoR cDNA. These observations suggest that the cloned cDNA for human EpoR alone does not allow generation of the complete EpoR in nonhematopoietic cells and that the 105-kD Epo-binding protein may represent the product of an as yet unidentified gene that is expressed in hematopoietic cells. 0 7995 by The American Society of Hematology.
the identified EpoR represents a 55-kD core polypeptide, and the molecular mass of mouse EpoR appears to be 66 to 72 (or 78) kD in Western blot and immunoprecipitation analyses with EpoR-specific antibodies.""3 However, conflicting ideas have been presented on the nature of the 85-to 95-kD (middle-sized) and 100-to 110-kD (largest) proteins that can be cross-linked to human Epo. Sawyer et al showed by peptide mapping that the 85-kD and 105-kD proteins in mouse spleen cells that have been infected with Friend spleen focus-forming virus (F-SFFV) have similar amino acid sequences, suggesting that these two proteins originate from the same gene.14 A similar interpretation has been presented by Mayeux et al. ' They showed that the 85-kD and 100-kD proteins that can be cross-linked to human Epo in mouse erythroleukemia (MEL) cell lines are immunologically distinct from the 66-kD protein that can be precipitated by an antibody against a product of the cloned mouse EpoR. Using a mutated EpoR, the same result was obtained by Quelle et al,I5 who showed that both the 105-kD (largest) and the 85-kD (middle-sized) proteins that can be crosslinked to human Epo are different from the product of the cloned mouse EpoR cDNA. However, Miura et all0 reported that the 105-kD (largest) as well as the 66-kD (smallest) proteins that can be cross-linked to human Epo are the products of the cloned mouse EpoR cDNA, and that the middlesized protein of 95 kD is encoded by another gene.
To resolve this confusion, we undertook a direct comparson of the results of cross-linking of labeled human Epo using three lines of cells that expressed human native EpoR and two lines of cells transfected with cDNA for human EpoR. The results of our cross-linking studies are also compared with those of Northern blot analysis.
STRUCTURE OF EpoR ON HUMAN CELL LINES 107
cells with erythroid features, which were maintained in RPMI 1640 that contained 5% FCS with 10 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; in the case of TF-1 and UT-7) or 10 U/mL Epo (in the case of F-36E). F-36E cells were washed twice in RPMI 1640 medium 1 day before each cross-linking experiment, and they were resuspended in the same medium with the exception of Epo, which was replaced by 10 ng/mL GM-CSF.
Expression vectors, transfection, and selection of drug-resistant clones. Human EpoR cDNA,I9 in the expression vector BCMGSnee:' was kindly provided by Dr K. Nakauchi of Tsukuba University, Tsukuba, Japan (designated BCMGSneohEpoR). A HindIIIPst I fragment that encompassed the entire cDNA for human EpoR was isolated from this plasmid and was inserted downstream of the SR-a promoter in the expression vector pSSR cy2' to yield pSSR a/ hEpoR. Transfection was performed using a Gene Pulser System (Bio-Rad, Richmond, CA) in accordance with the manufacturer's instructions. In brief, subconfluent cells were detached by treatment with a buffer that contained 0.1% trypsin, 0.02% EDTA, and Dulbec-CO's phosphate-buffered saline (PBS), and they were washed twice with ice-cold PBS and once with K-PBS (30.8 mmol/L NaCI, 120.7 mmol/L KCl, 8.1 mmol/L Na2HP04, 1.46 mmol/L KH,PO,). Then 2 X IO6 cells were resuspended in 200 pL of K-PBS, transferred to the cuvette, and mixed with 5 pg of plasmid (BCMGSneohEpoR for COS-l and AV-3 cells, and pSSR a/hEpoR for COS-I cells). After a 15-minute incubation on ice, the DNA was introduced into the cells by electroporation at 470 V, 25 pF, and 200 R. Cells were then incubated at room temperature for 10 minutes and transferred to DMEM that contained 5% FCS in a 14-cm tissue-culture dish. In the case of COS-l cells transfected with pSSR a/hEpoR (COS/ hEpoR), each cross-linking study was performed after a 60-to 72-hr incubation that followed electroporation. In the case of COS-1 cells and AV-3 cells (COShlGShEpoR and AV-3/MGShEpoR), neomycin-resistant cells were selected in the presence of G-418 (Geneticin; GIBCO, Grand Island, NY) at a concentration of 400 Cytokines and radiolabeling. Recombinant human Epo and GM-CSF were kindly provided by Kirin Brewery CO Ltd (Maebashi, Japan). Epo was iodinated by the chloramine-T method as described previously.22 In brief, 6 pL of carrier-free recombinant human Epo (1.25 mg/mL), 9 pL of 0.3 m o m sodium-phosphate buffer (pH 7.4), 10 pL of Na "' I (100 mCi/mL; ICN Biomedicals, Costa Mesa, CA), 45 pL of distilled water, and 10 pL of Chloramine T (30 pg/mL in phosphate buffer, pH 7.4) were incubated at room temperature for 14 minutes. The reaction was stopped by addition of 10 pL of sodium metabisulfate (60 pg/mL in phosphate buffer) and incubation for a further 5 minutes. Then free Na ' "I was removed from the reaction mixture by fractionation through a prepacked column of Sephadex G25 (Pharmacia LKB, Uppsala, Sweden). The specific radioactivity of iodinated Epo ('z'I-EpO) ranged from 3.6 X lo7 cpm/ Southern blot analysis. High molecular-weight genomic DNA was prepared from the three lines of cells that were responsive to human Epo, as described above, and from human peripheral blood mononuclear cells by the standard procedure.23 Ten micrograms of each DNA were digested to completion with restriction endonucleases. The DNA fragments were subjected to electrophoresis in a 0.8% agarose gel, transferred to a nylon filter (Amersham, Buckinghamshire, UK), and allowed to hybridize with a probe in 50% formamide at 42°C overnight. The probes used were generated by labeling fragments of a human EpoR cDNA (HindIII-Bgm and BglII-Psr I fragments) with [32P]-deoxycytidine triphosphate (dCTP). The filter was washed in 0.5 X saline sodium citrate (SSC) plus 0.1% sodium dodecyl sulfate (SDS) at 65°C and subjected to autoradiography.
Northern blot analysis. Total cellular RNA was prepared from the three Epo-responsive cell lines described above by the acid guapg to 10.6 X 10' Cpdpg. nidinium thiocyanate method.24 F-36E cells were cultured in the presence of GM-CSF or Epo before the preparation of RNA. The other two cell lines were cultured in the presence of GM-CSF alone. Twenty micrograms of each RNA were subjected to electrophoresis in a 1.2% agarose gel that contained 3% formaldehyde. RNA was then transferred to a nylon filter (Amersham) and allowed to hybridize with a probe in 50% formamide at 42°C overnight. The probe used was generated by labeling a 1,294-bp Pst I fragment of a human EpoR cDNA with ["P]-dCTP. The filter was washed in 0.1 X SSC plus 0.1% SDS at 65°C and subjected to autoradiography.
Binding assay with '25Z-Ep0. Subconfluent cultures of the three Epo-responsive cell lines described above were cultured with 10 ng/ mL GM-CSF and cells were harvested without starvation for growth factors. Each sample of 2.5 X IO6 cells was washed three times with binding buffer (50 mmol/L HEPES, pH 7.5, 0.1% bovine serum albumin [BSA] and 0.02% NaN3 in minimum essential medium) and then incubated at 37°C for 1 hour in 200 pL of the binding buffer plus various concentrations of '251-Epo with or without at least a 100-fold excess of unlabeled Epo. The cells were layered onto 200 pL of chilled FCS in tapered tubes. These tubes were centrifuged at 185 g for 10 minutes and then the tips were cut off just above the cell pellets. The radioactivity of each pellet was determined with a gamma counter. Specific binding was calculated by subtracting the radioactivity obtained in the presence of unlabeled Epo (nonspecific binding) from that obtained in the absence of unlabeled Epo (total binding). The number and the affinity of Epobinding sites were determined from a Scatchard plot" prepared from data from duplicate samples. Cross-linking study. Cells were harvested and washed twice with ice-cold PBS. Then 1 to 3 X lo7 cells were incubated in 500 pL of binding buffer (50 mmoVL HEPES, pH 7.5, 0.1% BSA, and 0.02% NaN3 in MEM) with 2 nmoVL "'I-Epo at room temperature for 120 minutes. The COS-l and AV-3 transfectants that had been cultured in 14-cm tissue-culture dishes were detached by scraping. After incubation, cells were washed twice with ice-cold PBS, resuspended in PBS plus 0.8 mmol/L disuccinimidyl suberate (DSS), and incubated at 4°C for 30 minutes. Antibodies and immunoprecipitation. Two monoclonal antibodies (MoAbs) against human EpoR, mh2EW7.9.2. and mh2ER/16.5.1, were kindly donated by Genetics Institute, Inc. (Cambridge, MA). These antibodies were raised against the product of the cloned human soluble-form EpoR cDNA. In the experiment of immunoprecipitation, 3 X IO' cells of each cell line were prepared and cross-linked described above. After the solubilization of cells, a half of the clear supernatant of each cell lysate was subjected directly to SDS-PAGE and a remaining half of supernatant was mixed with mh2EW7.9.2. or mh2EW16.5.1. at 4°C for 2 hours. Then the complexes were precipitated by Protein G Sepharose 4 Fast Flow (Pharmacia LKB, Uppsala, Sweden) at 4°C for 30 minutes under continuous agitation. After centrifugation at 330 g, the beads were washed by lysis buffer three times and were subjected to SDS-PAGE analysis. responsive cell lines in a comparison with that of the gene in the normal human genome to investigate possible modification of the EpoR gene in these cells. Previous studies showed the rearrangement and amplification of the EpoR gene in TF-l" and UT-7'* cells. Our results were consistent with these earlier results. In addition, we found that the F-36E cells also contained several copies of the EpoR gene, but we did not find any obvious rearrangements in the F-36E cells (Fig 1, A and B) . To the extent that we examined it, the EpoR gene in F-36E escaped significant alterations, as compared with the gene in the other two cell lines, in terms of gene structure.
RESULTS

Southern blot analysis of the gene for human EpoR in various lines of human hematopoietic cells. First, we examined the structure of the human EpoR gene in three Epo-
Northern blot analysis of various lines of human hematopoietic cells. Expression of mRNA that corresponded to Cross-linking anal.vsis with I2'I-Epo in the human hematopoietic cell lines. When the three lines of human Eporesponsive cells were subjected to the cross-linking protocol, two major cross-linked species of 140 kD and 120 kD were identified as specific ligand-receptor complexes (Fig 4) . The cross-linked complex of 105 kD was also clearly formed in F-36E cells and it was formed at low levels in UT-7 cells, but it was not formed in T F -I cells. When the molecular mass of Epo was subtracted, these values corresponded to 105 kD, 85 kD, and 70 kD, respectively. In addition to the 105-kD ligand-receptor complex, a difference was noted in the relative levels of the 120-kD and 140-kD complexes. The 120-kD band (middle-sized complex of the three indicated) was far more prominent than the 140-kD band (large complex) in F-36E. In UT-7, the 120-kD band appeared to be slightly more intense than the 140-kD band. The two bands appeared at similar intensities in the case of T F -I cells. Proteolysis may possibly have influenced these observations, but they were highly reproducible among independent experiments. It was of particular interest that the level of expression of the cloned EpoR was closely correlated with the intensity of the 105-kD band and with the ratio of the intensities of the 120-kD and 140-kD bands in the three Epo-dependent cell lines.
Cross-linking analysis with 1251-Epo in the hematopoietic cell lines and in COS cells transfected with human EpoR. We directly compared the cross-linking patterns obtained with '2'I-Epo from the COShEpoR cells, COS/MGShEpoR cells, and the F-36E cells by SDS-PAGE on the same gel (Fig 5) . Moreover, in order to examine other nonhematopoietic cells, we established a stable transformant of AV-3 (a human amniotic cell line) that expressed human EpoR (AV3MGShEpoR) and subjected it to the cross-linking study with '''I-Epo, together with F-36E cells (Fig 6) . In the three transfectants, only two major cross-linked complexes were detected. The apparent molecular masses of these complexes were approximately 1 15 kD and 105 kD in each transfectant. The two bands appeared to correspond to the smallest and middle-sized complexes obtained from the F-36E cells (see Figs S and 6) except for a slight difference in the mass of the 115-kD to 120-kD complex among them. The 140-kD complex showed in the three lines that expressed human native EpoR was absent from the COS-I and AV-3 transfectants. Furthermore, the relative levels of intensity of the two bands detected in the case of COS-l and AV-3 transfectants were distinctly different from those in the native EpoR-expressing cells; the 105-kD band was more prominent than the 1 IS-kD band (these bands may have corresponded to the bands of the smallest and middle-sized complexes in the three erythroid cell lines, respectively), whereas the smallest complex gave the weakest band in the three human Eporesponsive cell lines, as described above. To examine whether these results would also hold true for mouse EpoR, cross-linking studies were also performed with a COS-l transfectant that expressed mouse EpoR cDNA (COS/ mEpoR) and a mouse erythroleukemia cell line, FS-5,"" as mouse hematopoietic cells. The results for COS/mEpoR were essentially the same as those for COSlhEpoR and COS/ MGShEpoR (data not shown), as previously reported.>' In the FS-S cells, the level of expression of the EpoR mRNA is extremely high because of retroviral insertion in the 5' upstream region of the EpoR gene.3' The results for the FS-S cells were similar to those for the three human Eporesponsive cell lines, except that the band of the smallest 109 complex was the most intense among the three bands (data not shown), as described previously by Hino 
et al.>'
Immunoprecipitation qf the cross-linked molecule. Before the experiment of immunoprecipitation of the crosslinked molecule, we confirmed the specificity of the antibodies. The COSlhEpoR cells and mock-transfected COS-1 cells were labeled with ["SI-methionine. Both mh2EW7.9.2. and mh2EW16.5.1. antibodies could specifically immunoprecipitate the 70-kD molecule only from COSlhEpoR cell lysates (data not shown). Then we performed immunoprecipitation of the cross-linked molecules using these two antibodies. We found that mh2EW7.9.2. could precipitate the ligandreceptor complex, but mh2EW16.S.l. could not. The patterns of cross-linked bands after immunoprecipitation using mh2EW7.9.2. were the same as before immunoprecipitation (Fig 7) . In nonhematopoietic cells which expressed human EpoR, COSlhEpoR, and AV-3/MGShEpoR, two major cross-linked complexes of 105 kD and I IS kD were observed, but the 140-kD complex that was shown in F-36E cells was never observed. In this study, we first analyzed EpoR in three lines of human leukemic cells, TF-I, UT-7, and F-36E, by Southern blotting, Northern blotting, and Scatchard analysis. The EpoR genes of all three cell lines were amplified as compared with that in the normal human genome. The EpoR genes of TF-I and UT-7 have been rearranged, as reported previou~ly.~'~~* However, the EpoR gene of F-36E was apparently not rearranged, as far as we could tell from the present analysis (Fig l) .
The level of expression of the cloned EpoR mRNA was very much higher in F-36E cells, a line of erythroid-differentiating leukemic cells that requires GM-CSFhnterleukin-3 (IL-3)Epo. than in the other two cell lines that we examined (Fig 2) . It was also evident that the level of mRNA was constant in F-36E cells grown in the presence of GM-CSF or Epo, suggesting that the Epo does not up-regulate or down-regulate the EpoR mRNA. The regulation of the level of mRNA for EpoR by cytokines has been described in UT-7 cells by Hermine et al.3h They found that the EpoR mRNA was down-regulated by GM-CSF more significantly than by Epo. Our results are different from theirs. It may be that the nature of the regulation of the level of EpoR mRNA by Epo or GM-CSF differs between these two cell lines. Because both of these lines are leukemic cells, it is unclear how the level of EpoR mRNA is regulated by these cytokines in normal erythroid progenitor cells. The level of the mRNA in UT-7 was much lower than that in F-36E but higher than that in TF-I cells. However, we note that this comparison Bwnd "l-Epo holds only for UT-7 and TF-1 cells that had been grown in the presence of GM-CSF at the time when the RNA was prepared.
We performed binding assays with 1251-Ep0 to investigate the EpoR on the surface of cells of each line. Scatchard plots (Fig 3) showed a single type of binding affinity for all three cell lines.35 The calculated number of binding sites for each cell line was not correlated with the level of expression EpoR Bound "'I-Epo mRNA that was shown in Fig 2. We cannot explain the discrepancy between these results but it is probable that the existence of unknown components of EpoR affected the results of the binding assay.
The cross-linking patterns with '251-Ep0 were also compared among the three Epo-responsive cell lines (Fig 4) . The Previous reports have been inconsistent with respect to the interpretation of the middle-sized (85-to 95-kD) and largest (100-to 115-kD) Epo-binding proteins shown in the cross-linking studies. Sawyer et all' reported that these two proteins are similar in amino acid sequence, and suggested that they might be derived from the same gene. Hosoi et al." argued that these proteins are poorly glycosylated and, thus, are too large to be the products of the identified EpoR mRNA. Mayeux et al' showed that the middle-sized and largest Epo-binding proteins are immunologically dissimilar to the smallest one, which is recognized by an antibody raised against the product of the cloned mouse EpoR cDNA. Using mutated mouse EpoR, Quelle et al obtained evidence that both the middle-sized and the largest Epo-binding proteins are not derived from the cloned EpoR. A contradictory observation was reported by Miura et al.'" They proposed that the largest and the smallest Epo-binding proteins (of the three that they detected in a mouse IL-3-dependent myeloid cell line [DA-31 that had been transfected with a mouse EpoR cDNA) are products of the transfected EpoR cDNA and, moreover, that only the middle-sized Epo-binding protein is the product of another gene.
105-kD band corresponding to the 70-kD EpoR protein was strongest in F-36E cells and was weakly detected in the case
In no previous cross-linking studies has any one ever analyzed Epo-binding proteins in hematopoietic cells and nonhematopoietic EpoR-transfectants together on the same gel, so there has been some confusion about the correspondence between cross-linked molecules from such cells. To resolve the confusion, we made direct comparisons of cross-linking patterns between human Epo-responsive cell lines and nonhematopoietic cells that had been transfected with human EpoR cDNA on the same gel. In our experiments, the most significant difference was the absence of the band of the largest 140-kD complex that corresponds to the 105-kD Epobinding protein in the latter, although the direct comparison clearly showed the existence of this band in the case of F-36E cells. We also addressed the question of whether there are any differences in the cross-linked complexes detected in analysis of different nonhematopoietic cells because the previous studies of EpoR in nonhematopoietic EpoRtransfectants were restricted to COS cells. As shown in Figs 5 and 6, cross-linking patterns were essentially the same in the COS cells and AV-3 cells. The 85-kD and 70-kD proteins were cross-linked to Epo in the AV-3 cells, as well as in COS cells, whereas the 105-kD protein was not, as described above. Considering these results and the results for hematopoietic cell lines shown in Fig 4, it is evident that the 105-kD Epo-binding protein (corresponding to the 140-kD band), which is expressed in hematopoietic cell lines, is never present in nonhematopoietic EpoR-transfectants, and this protein must be the product of an as yet unidentified gene.
For further characterization of cross-linked molecules, we performed immunoprecipitation after cross-linking using MoAb against human EpoR. Any significant changes were not observed after immunoprecipitation. In nonhematopoietic cells transfected with human EpoR cDNA, the 85-kD and 70-kD proteins cross-linked to Epo were immunoprecipitated with an antibody against human EpoR. In addition to the two proteins, the 105-kD Epo-binding protein (corresponding to the 140-kD band) was also immunoprecipitated in F-36E cells (Fig 7) . This result suggests that the 105-kD protein in F-36E cells constitutes the erythropoietin receptor together with the cloned EpoR, and is coimmunoprecipitated by the specific antibody against the cloned EpoR. However, there still remains a minor possibility of the 105-kD protein TAKAHASHI ET AL being directly precipitated by the cross-reaction of the antibody, though we confirmed the specificity of the antibodies by metabolic labeling.
One intriguing observation that we made is that the band of the middle-sized 120-kD cross-linked complex (which corresponded to the 85-kD Epo-binding protein) in the F-36E cells was extremely prominent compared with the other two bands and the band of the same-sized complex in other cells studied (Fig 4) . When we compare the ratio of intensities of the 120-and 140-kD bands, we see that it was much lower in UT-7 than in F-36E cells, but higher in UT-7 than in TF-1. Moreover, the level of expression of cloned EpoR mRNA, the detectability of the smallest cross-linked species, and the ratio of the middle-sized and largest cross-linked species are parallel to the rank order of the three cell lines (F-36E > UT-7 > TF-l). This correlation suggests the possibility that the middle-sized Epo-binding protein is related to the cloned EpoR mRNA.
With respect to the structure of EpoR, there is much indirect evidence that EpoR exists as a complex that contains a second subunit. Although there is a consensus that the homodimerization of cloned EpoR is indispensable for signal transduction of E~o ,~*~' this dimerization alone seems, from some experimental results, to be insufficient for formation of the complete active EpoR on the surface of hematopoietic cells. For example, the cloned EpoR cannot transduce a growth signal in nonhematopoietic cell lines, and its binding affinity is different from that of EpoR on hematopoietic cells~.4.8.~n.x (Fig 3 and our unpublished data, October 1993) . Chiba et a142.43 showed that chimeric receptors that consist of the extracellular domain of EpoR and the cytoplasmic domains of other cytokines can transduce the Epo signal in hematopoietic cell lines.44 This result also suggests the existence of some other component of EpoR in hematopoietic cells.
Considering our present data and the data by others together, we can conclude with some confidence that an as yet unidentified molecule forms the erythropoietin receptor on hematopoietic cells together with the cloned EpoR, and that the largest 105-kD Epo-binding protein is the product of an unidentified gene. For elucidation of the complexities of the overall structure of EpoR, the identification of this gene is now absolutely essential. For personal use only. on March 31, 2017. by guest www.bloodjournal.org From
